Orthofix Medical Inc. (OFIX)
$9.79-2.20%Close
SELLCRISIS · day 2
Key stats
Short interest · FINRA settlement 2026-07-31
- Market cap
- $396M
- Avg volume
- 395.4K
- Beta
- 0.67
- P/E (TTM)
- -6.38
- Short % float
- 5.29%
- Days to cover
- 7.4
- SI change
- -15.4%
- 1W
- -2.39%
- 1M
- -12.98%
- 3M
- -8.93%
- YTD
- -34.03%
- vs SPY 1W
- -1.20%
- vs SPY 1M
- -16.30%
- vs SPY 3M
- -11.32%
- vs SPY YTD
- -45.78%
Sector peers
Same-sector names ranked by LOPJLB quality proximity · Healthcare
- ALKSSELLAlkermes plcBEARQ 6$48.87+1.12%
- AMRXSELLAmneal Pharmaceuticals, Inc.BEARQ 14$17.78-0.73%
- ONCOSELLOnconetix, Inc.CRISISQ 6$0.66+1.54%
- BDTXBUYBlack Diamond Therapeutics, Inc.RECOVERYQ -6$2.15-2.71%
- ICUIBUYICU Medical, Inc.BULLQ 22$182.55-0.16%
- NIVFSELLNewGenIvf Group LimitedCRISISQ -32$0.49-15.52%
- BDXBUYBecton, Dickinson and CompanyBULLQ 18$190.74-0.66%
- ADILBUYAdial Pharmaceuticals, Inc.RECOVERYQ -14$5.40-13.18%
- CNSPBUYCNS Pharmaceuticals, Inc.RECOVERYQ -27$5.94+1.89%
- MCKBUYMcKesson CorporationRECOVERYQ 12$873.79+1.73%
- MTNBSELLMatinas BioPharma Holdings, Inc.CRISISQ -5$0.20+0.00%
- SRTABUYStrata Critical Medical, Inc.RECOVERYQ 1$5.97-4.33%
Industry peers
FMP comparable companies · ranked by market cap
- BFLYBUYButterfly Network, Inc.$2.5BRECOVERYQ 12$9.55-6.28%
- ABSIBUYAbsci Corporation$1.6BCRISISQ 1$9.55-7.43%
- MLTXSELLMoonLake Immunotherapeutics$1.3BCRISISQ 4$15.76-2.47%
- AVNSSELLAvanos Medical, Inc.$1.2BBULLQ 10$24.99+0.04%
- SIBNBUYSI-BONE, Inc.$885MRECOVERYQ 5$19.96-2.45%
- VREXBUYVarex Imaging Corporation$779MBULLQ -5$18.51+0.05%
- ESPRBUYEsperion Therapeutics, Inc.$661MBULLQ 1$3.18+0.00%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 19
- VALUE
- 16
- GROWTH
- 48
- GARP
- 5
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-8.4%
REV YoY-
ROE-14.1%
EPS YoY-
ROA-7.1%
GROSS70
OP-3
NET-7
[VALUATION]
P/E TTM-6.38
P/E FWD-
SECTOR PE22.66
INDUSTRY PE24.61
P/B0.93
P/FCF-
EV/EBITDA4.92
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E54.67
ALTMAN Z-
CURR RATIO2.84
ND/EBITDA-
BETA0.67
